Damora Therapeutics (DMRA) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Precigen (PGEN) over the past year, gaining 38.5% versus a gain of 8.5%. Over five years, PGEN leads with a +9.1% price change compared with -68.8% for DMRA. Precigen is the larger company by market cap ($1.51 billion vs $1.44 billion), about 1.1 times the size.
On valuation, Damora Therapeutics trades at a lower trailing P/E (13.6x vs 38.3x for Precigen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | PGEN |
|---|---|---|
| Share price | $23.22 | $4.21 |
| Market cap | $1.44B | $1.51B |
| 1-day change | -4.44% | +1.20% |
| YTD return | +0.91% | +0.72% |
| 1-year return | +38.46% | +8.51% |
| 5-year return | -68.83% | +9.07% |
| P/E ratio (TTM) | 13.58 | 38.27 |
| EPS (TTM) | $1.71 | $0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | $-209.84M | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $38.33 | $8.98 |
| 52-week low | $15.76 | $3.04 |
| Distance from 52-week high | -39.41% | -53.12% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +101.46% | +224.70% |
| Average volume | 584.28K | 5.68M |
| Shares outstanding | 61.90M | 358.55M |
| Employees | 7 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed PGEN by 30.0 percentage points over the past year.
- Precigen trades at a higher earnings multiple (38.3x vs 13.6x trailing P/E).
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
DMRA vs PGEN FAQ
Which is bigger, Damora Therapeutics or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.44B for Damora Therapeutics (DMRA).
Which stock has performed better over the past year, DMRA or PGEN?
DMRA returned +38.46% over the past 12 months, compared with +8.51% for PGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DMRA or PGEN?
DMRA has the lower trailing P/E at 13.6, versus 38.3 for PGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Damora Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.